All In Biotech

Drug Trial Radar · NCT01863550

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,087 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,087

Actual

Start

Dec 6, 2013

Primary completion

Dec 31, 2026

Study completion Feb 5, 2034

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
May 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma

Conditions

  • Plasma Cell Myeloma

Interventions

  • BortezomibDrug

    Given SC or IV

  • CarfilzomibDrug

    Given IV

  • DexamethasoneDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Optional correlative studies

  • LenalidomideDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) for the maintenance analysisTime frame: From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years
  2. Progression-free survival for the induction analysisTime frame: From the induction randomization until the earlier of progression or death due to any cause, assessed up to 15 years

Locations

920 sites in 2 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Veteran's Administration Medical Center

    Little Rock, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • Sutter Davis Hospital

    Davis, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Saint Jude Medical Center

    Fullerton, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Kaiser Permanente-Redwood City

    Redwood City, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

Showing 40 of 920 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.